Zhang Y, Zou W, Zhu X, Jiang L, Gui C, Fan Q, Tu Y, Chen J
Hubei Cancer Hospital - Department of Head and Neck Surgery, Wuhan, China.
First People's Hospital of Yichang - Department of General Surgery II, Yichang, Hubei, China.
Acta Endocrinol (Buchar). 2022 Jan-Mar;18(1):86-92. doi: 10.4183/aeb.2022.86.
Radioactive iodine (RAI) therapy is a mainstay adjuvant treatment for thyroid cancer. Administration of RAI therapy after total or near-total thyroidectomy has shown a survival advantage in numerous properly selected patients. However, the role of RAI therapy after reoperation for persistent or recurrent differentiated thyroid carcinomas (DTCs) is unclear. One reason may be the possible downregulation of the I- transport system after primary surgery. RAI is transported by the sodium iodide symporter (NIS), PENDRIN, anoctamin 1 (ANO1) and cystic fibrosis transmembrane conductance regulator (CFTR) and emits β particles that destroy follicular cells. The identification of pathways of iodide (I-) transport has allowed use of the transport system to render tumours susceptible to RAI treatment gene therapy. This review focuses on the effect of RAI therapy in follicular cell-derived thyroid cancers and offers potential novel targets that enable improved radioiodine uptake and thus an improved prognosis of thyroid cancer.
放射性碘（RAI）治疗是甲状腺癌的一种主要辅助治疗方法。在全甲状腺切除或近全甲状腺切除术后进行RAI治疗，已在众多经过适当选择的患者中显示出生存优势。然而，对于持续性或复发性分化型甲状腺癌（DTC）再次手术后进行RAI治疗的作用尚不清楚。一个原因可能是初次手术后碘转运系统可能下调。RAI由钠碘同向转运体（NIS）、PENDRIN、八聚体蛋白1（ANO1）和囊性纤维化跨膜传导调节因子（CFTR）转运，并发射β粒子来破坏滤泡细胞。碘（I-）转运途径的确定使得利用该转运系统使肿瘤对RAI治疗基因疗法敏感成为可能。本综述重点关注RAI治疗在滤泡细胞源性甲状腺癌中的作用，并提供潜在的新靶点，以提高放射性碘摄取，从而改善甲状腺癌的预后。
